Kazuto Kato: the ethics of editing humanity
By Gary Humphreys,
Bulletin of the World Health Organization
| 09. 01. 2021
Photo from Kazuto Kato’s biography at
University of Oxford’s Faculty of Law
Gary Humphreys talks to Kazuto Kato about the ethical and societal challenges posed by biotechnologies that allow for the editing of the human genome.
Q: You started out working in developmental biology. How did you become interested in the field of ethics and governance of biomedicine?
A: As a student, I always had a broad interest in the societal issues related to biological science and its application and was actually a member of a student club that focused on such issues. I was also encouraged to look at issues outside the laboratory by my uncle, Professor Shuzo Nishimura, a pioneer in the field of health economics in Japan. Of course, I also had nine years at Kyoto University and four years at the University of Cambridge with Sir John Gurdon studying biology, with a focus on stem cell biology and genomics. This background has helped me navigate what is sometimes complex terrain.
Q: Given that complexity, can you start by giving our readers a simple definition of genomics...
Related Articles
By Carissa Wong, New Scientist | 07.08.2026
Healthy lambs have been born via an experimental form of in vitro fertilisation (IVF) that coaxes highly immature eggs to become mature ones in the lab. This is the first time the approach has been demonstrated in a large animal...
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...